Nick Goeden

Founder, Chief Technology Officer @ Capsida

Was a post-doctoral researcher in the laboratory of Viviana Gradinaru, Ph.D., at Caltech
Met Nicholas Flytzanis, then a Ph.D. student, while working in Gradinaru's lab
Co-envisioned a translational focus for the AAV gene therapy platform leading to the founding of Capsida
Approached Gradinaru with a concept for a gene therapy company over lunch at a restaurant named Nick's

Capsida develops targeted, non-invasive intravenous gene therapies for rare and common diseases, with a focus on CNS and ophthalmology disorders.